Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

- PMLiVE

The Lucid Group Guide

We work hard at Lucid Group. Transforming lives, it's not a walk in the park. We’re a team. In fact, we are many teams. Working together to discover, define, design,...

Lucid Group Communications Limited

Our #LucidLife

We asked our people: Why do you do what you do? - What makes you get out of bed in the morning? The responses had a common theme - it's...

Lucid Group Communications Limited

- PMLiVE

Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s

Patients from a small phase 2a study saw their ADAS-Cog11 scores improve by 4.4 points

Happiness and wellbeing: you can have both, but they’re not the same thing

"Wellbeing needs to remain central to leadersip", writes Paul Hutchings, founder of fox&cat. In this article Paul and his network explain the difference between wellbeing and happiness. And how problems...

Fox&Cat

- PMLiVE

Market shaping for better healthcare decisions

By Tim Warren

- PMLiVE

bluebird bio’s CALD gene therapy Skysona gains positive opinion from CHMP

CHMP's marketing authorisation recommendation is a step towards gaining EU approval

Dementia Action Week

The future of dementia and the important role of healthcare communication in raising awareness

At Bedrock Healthcare Communication we are proud to help spread awareness of dementia with the ultimate goal to improve the lives of patients and carers

Bedrock Healthcare Communications

- PMLiVE

BeiGene, Novartis’ tislelizumab report promising topline results in nasopharyngeal cancer

In 2018, 46.9% of global cases of nasopharyngeal cancer occurred in China

- PMLiVE

Paula Hensler joins Havas Just:: as scientific director

Hensler will lead the scientific strategy and content for the healthcare comms agency

- PMLiVE

Beyoncé vs Paul Simon: achieving launch excellence

By Isabelle Geoghegan

- PMLiVE

BMS links up with Exscientia for $1.2bn AI drug discovery deal

Deal focuses on the use of AI to discover drug candidates across a number of therapeutic areas

Roche Basel Switzerland

Roche’s Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Interim results from the phase 3 study to be presented at ASCO 2021

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links